EMV Capital advised on £740k oversubscribed funding round for 5G and satellite phased array designer Sofant Technologies London, UK - 28 April 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability, technology investment and commercialisation group, announces that its corporate finance and venture capital division EMV Capital Ltd ( EMVC ) advised on a £740k oversubscribed top-up fundraise for its Advised Portfolio Company, designer Sofant Technologies ( Sofant ).
The fundraise builds on last year s £2.3m pre-series A round for Sofant. Participation in the round included key existing investors, including Kelvin Capital and the Scottish Investment Bank. The funding round included a price per share uplift of 40% in less than one year since its last investment round in July 2020 - reflecting strong developments at Sofant over the period.
c. $60m Funding Commitment by Brazilian government for Clinical Development and Commercialisation of PDS Consortium s COVID-19 Vaccine London, UK - 11 March 2021 - NetScientific plc (AIM: NSCI), the life sciences and sustainability technology investment and commercialisation Group, announces that PDS Biotech s proprietary Versamune®T-cell activating technology, today announced that its COVID-19 vaccine consortium jointly run by PDS consisting of Farmacore Biotechnology and Blanver Farmoquímica, has received a commitment from the Secretary for Research and Scientific Training of the Ministry of Science, Technology and Commercialisation of Brazil ( MCTI ) to fund up to approximately US$60 million to support the clinical development and commercialization of a novel, Versamune®-based, second generation COVID-19 vaccine in Brazil.
PDS Biotech Announces Preliminary Efficacy Achievement in Phase II Combination Trial of PDS0101 Led by the National Cancer Institute · The National Cancer Institute s (NCI) Phase II clinical study of PDS Biotech s PDS0101 for HPV-associated cancers has achieved its preliminary objective response. · Full enrollment for the Phase II trial is triggered by observation of 3 objective responses in continued evaluation of the initial group of 8 patients · Milestone for treatment of HPV-associated cancers NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, announces that its portfolio company PDS Biotechnology Corporation ( PDS ) (Nasdaq: PDSB) has achieved its preliminary objective response for the National Cancer Institute s (NCI) Phase II clinical study of PDS0101 for the treatment of advanced human papill